Twist Bioscience manufactures synthetic DNA — custom-made strands of DNA written on silicon chips — and sells them to life sciences researchers, diagnostic companies, pharma and biotech firms, and academic institutions. Customers use Twist's synthetic DNA as a building block for drug discovery, diagnostic test development, gene editing, and enzyme engineering. Twist operates two product groups: DNA Synthesis and Protein Solutions (~45% of revenue), which covers synthetic genes, gene fragments, oligo pools, IgG antibodies, and fee-for-service antibody discovery programs; and NGS Applications (~55% of revenue), which covers target enrichment panels and library prep kits used by diagnostic companies to build clinical tests for cancer, rare disease, and prenatal screening. Twist's manufacturing platform is a proprietary silicon chip-based synthesis process that enables high throughput, low error rates, and fast turnaround — its flagship "Express" portfolio delivers custom genes in roughly five business days. In NGS, once a diagnostic customer validates a test using Twist's tools, switching costs are high, making this a largely recurring revenue stream that grows as patient testing volumes rise. The business has a high fixed-cost manufacturing structure, so gross margins expand as revenue scales. Twist's near-term growth priorities include serving AI-driven drug discovery customers, commercializing a 12-hour tumor-informed cancer monitoring panel (MRD Express), and expanding its SynBio customer base in academic and industrial biotech markets. Twist manufactures in the U.S., which is increasingly relevant given customer interest in domestic supply chains for synthetic DNA.